Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib - Takeaways - MDSpire

Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib

  • By

  • Shi-yu Huang

  • Min Hu

  • Yu-jie Chen

  • Jia-chen Liu

  • Zhi-yuan Yao

  • Zhi-yuan Chen

  • Xiu-heng Liu

  • Lei Wang

  • December 15, 2025

  • 0 min

Share

  • 1

    Sunitinib, a tyrosine kinase inhibitor, is the standard first-line therapy for clear-cell renal cell carcinoma but poses a risk of cardiotoxicity.

  • 2

    Dapagliflozin, initially developed for type 2 diabetes, exhibits cardioprotective effects and may mitigate sunitinib-induced cardiotoxicity.

  • 3

    The cardiotoxic effects of sunitinib include left ventricular dysfunction, myocardial cell apoptosis, and oxidative stress.

  • 4

    Dapagliflozin's protective mechanism against sunitinib-induced cardiotoxicity operates through the AMPKα-PPARα pathway.

  • 5

    Understanding the mechanisms of sunitinib-induced cardiac toxicity is crucial for developing safer cancer therapies.

Original Source(s)

Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib

  • by Shi-yu Huang, Min Hu, Yu-jie Chen, Jia-chen Liu, Zhi-yuan Yao, Zhi-yuan Chen, Xiu-heng Liu, Lei Wang

  • December 15, 2025

Related Content

A Narrative Review of Atrial Fibrillation in the Perioperative Period Following Non-Cardiac Surgery

The effect of sodium restricted diet on the prognosis of heart failure patients: a systemic review and meta-analysis

Editorial: Cardiovascular risks in cardiovascular-kidney-metabolic syndrome: mechanisms and therapies